IL-15/sIL-15Rα gene transfer suppresses Lewis lung cancer growth in the lungs, liver and kidneys

Cancer Gene Therapy

Volumn 23, Issue 2-3, 2016, Pages 54-60

  Sun, H ^a   Liu, D ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; GEMCITABINE; GRANZYME B; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR ALPHA; MESSENGER RNA; PERFORIN; TRANSCRIPTION FACTOR T BET; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; GRANZYME; GZMB PROTEIN, MOUSE; IFNG PROTEIN, MOUSE; IL15RA PROTEIN, MOUSE; INTERLEUKIN 15 RECEPTOR; PERFORIN, MOUSE; PORE FORMING CYTOTOXIC PROTEIN; T BOX TRANSCRIPTION FACTOR; T-BOX TRANSCRIPTION FACTOR TBX21;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HYDRODYNAMICS BASED TRANSFECTION; KIDNEY; LEWIS CARCINOMA; LIVER; LUNG; MEDIAN SURVIVAL TIME; MOUSE; NATURAL KILLER T CELL; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CARCINOMA, LEWIS LUNG; GENE THERAPY; GENE TRANSFER; GENETICS; HUMAN; IMMUNOLOGY; KIDNEY NEOPLASMS; LIVER NEOPLASMS; LUNG NEOPLASMS; METABOLISM; NATURAL KILLER CELL; PATHOLOGY; PROCEDURES; SECONDARY; SURVIVAL RATE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD8; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; DEOXYCYTIDINE; FEMALE; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GRANZYMES; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-15; KIDNEY NEOPLASMS; KILLER CELLS, NATURAL; LIVER NEOPLASMS; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; PORE FORMING CYTOTOXIC PROTEINS; RECEPTORS, INTERLEUKIN-15; SURVIVAL RATE; T-BOX DOMAIN PROTEINS; T-LYMPHOCYTES;

EID: 84953425816     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2015.67     Document Type: Article

References (33)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics. 2015CA Cancer J Clin 2015; 65: 5-29.
2. Little AG, Gay EG, Gaspar LE, Stewart AK. National survey of non-small cell lung cancer in the United States: epidemiology, pathology and patterns of care. Lung Cancer 2007; 57: 253-260.
3. Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009; 27: 6251-6266.
4. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004; 202: 275-293.
5. Dutcher J. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology (Williston Park) 2002; 16: 4-10.
6. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 1996; 14: 7-17.
7. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006; 6: 595-601.
8. Steel JC, Waldmann TA, Morris JC. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci 2012; 33: 35-41.
9. Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 2002; 17: 537-547.
10. Bergamaschi C, Rosati M, Jalah R, Valentin A, Kulkarni V, Alicea C et al. Intracellular interaction of interleukin-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity. J Biol Chem 2008; 283: 4189-4199.
11. Rubinstein MP, Kovar M, Purton JF, Cho JH, Boyman O, Surh CD et al. Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc Natl Acad Sci USA 2006; 103: 9166-9171.
12. Dubois S, Patel HJ, Zhang M, Waldmann TA, Muller JR. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8 +/CD44high T cells and its antitumor action. J Immunol 2008; 180: 2099-2106.
13. Steel JC, Ramlogan CA, Yu P, Sakai Y, Forni G, Waldmann TA et al. Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help. Cancer Res 2010; 70: 1072-1081.
14. Cheng L, Du X, Wang Z, Ju J, Jia M, Huang Q et al. Hyper-IL-15 suppresses metastatic and autochthonous liver cancer by promoting tumour-specific CD8+ T cell responses. J Hepatol 2014; 61: 1297-1303.
15. Chang CM, Lo CH, Shih YM, Chen Y, Wu PY, Tsuneyama K et al. Treatment of hepatocellular carcinoma with adeno-associated virus encoding interleukin-15 superagonist. Hum Gene Ther 2010; 21: 611-621.
16. Bessard A, Sole V, Bouchaud G, Quemener A, Jacques Y. High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer. Mol Cancer Ther 2009; 8: 2736-2745.
17. Epardaud M, Elpek KG, Rubinstein MP, Yonekura AR, Bellemare-Pelletier A, Bronson R et al. Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res 2008; 68: 2972-2983.
18. Dubois S, Patel HJ, Zhang M, Waldmann TA, Muller JR. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8(+)/CD44 (high) T cells and its antitumor action. J Immunol 2008; 180: 2099-2106.
19. Stoklasek TA, Schluns KS, Lefrancois L. Combined IL-15/IL-15Ralpha immu-notherapy maximizes IL-15 activity in vivo. J Immunol 2006; 177: 6072-6080.
20. Jalah R, Rosati M, Kulkarni V, Patel V, Bergamaschi C, Valentin et al. Efficient systemic expression of bioactive IL-15 in mice upon delivery of optimized DNA expression plasmids. DNA Cell Biol 2007; 26: 827-840.
21. Rosati M, von Gegerfelt A, Roth P, Alicea C, Valentin A, Robert-Guroff M et al. DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge. J Virol 2005; 79: 8480-8492.
22. Schneider R, Campbell M, Nasioulas G, Felber BK, Pavlakis GN. Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation. J Virol 1997; 71: 4892-4903.
23. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999; 6: 1258-1266.
24. Li J, Yao Q, Liu D. Hydrodynamic cell delivery for simultaneous establishment of tumor growth in mouse lung, liver and kidney. Cancer Biol Ther 2011; 12: 737-741.
25. Chapoval AI, Fuller JA, Kremlev SG, Kamdar SJ, Evans R. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells. J Immunol 1998; 161: 6977-6984.
26. Johnson DH. Gemcitabine for the treatment of non-small-cell lung cancer. Oncology (Williston Park) 2001; 15: 33-39.
27. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005; 11: 6713-6721.
28. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-174.
29. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21: 3127-3132.
30. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 263-274.
31. Aerts JG, Hegmans JP. Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. Cancer Res 2013; 73: 2381-2388.
32. Ikeda R, Vermeulen LC, Lau E, Jiang ZS, Sachidanandam K, Yamada K et al. Isolation and characterization of gemcitabine-resistant human non-small cell lung cancer A549 cells. Int J Oncol 2011; 38: 513-519.
33. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WEE, Poddubskaya E et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-135.